Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma

Cancer Immunology, Immunotherapy

Volumn 64, Issue 10, 2015, Pages 1241-1250

  Guislain, Aurelie ^a,b   Gadiot, Jules ^a   Kaiser, Andrew ^a,c   Jordanova, Ekaterina S ^a,d   Broeks, Annegien ^a   Sanders, Joyce ^a   van Boven, Hester ^a   de Gruijl, Tanja D ^d   Haanen, John B A G ^a   Bex, Axel ^a   Blank, Christian U ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c MILTENYI BIOTEC GMBH   (Germany)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adoptive cell therapy; Myeloid derived suppressor cells; Renal cell carcinoma; Sunitinib; Tumor infiltrating lymphocytes

Indexed keywords

SUNITINIB; ANTINEOPLASTIC AGENT; EVEROLIMUS; INDOLE DERIVATIVE; INTERLEUKIN 2; PAZOPANIB; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; RAPAMYCIN; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CELL INFILTRATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MYELOID DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; ANALOGS AND DERIVATIVES; BONE MARROW CELL; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INDOLES; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MYELOID CELLS; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; PYRIMIDINES; PYRROLES; SIROLIMUS; SULFONAMIDES; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84940720838     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1735-z     Document Type: Article

References (37)

1. Golimbu M, Joshi P, Sperber A, Tessler A, Al-Askari S, Morales P (1986) Renal cell carcinoma: survival and prognostic factors. Urology 27:291–301
2. Coppin C, Le L, Porzsolt F, Wilt T (2008) Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev CD006017. doi:10.1002/14651858.CD006017.pub2
3. Albiges L, Choueiri T, Escudier B et al (2014) A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol 67:100–110. doi:10.1016/j.eururo.2014.04.006
4. Klapper JA, Downey SG, Smith FO et al (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113:293–301. doi:10.1002/cncr.23552
5. De Mulder PH, Oosterhof G, Bouffioux C, van Oosterom AT, Vermeylen K, Sylvester R (1995) EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer 71:371–375
6. Blank CU (2014) The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol 26:204–214. doi:10.1097/CCO.0000000000000054
7. Motzer RJ, Rini BI, McDermott DF et al (2014) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. doi:10.1200/JCO.2014.59.0703
8. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233–240. doi:10.1016/j.coi.2009.03.002
9. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR (2013) Deciphering signatures of mutational processes operative in human cancer. Cell Rep 3:246–259. doi:10.1016/j.celrep.2012.12.008
10. Heemskerk B, Kvistborg P, Schumacher TN (2013) The cancer antigenome. EMBO J 32:194–203. doi:10.1038/emboj.2012.333
11. van Rooij N, van Buuren MM, Philips D et al (2013) Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31:e439–e442. doi:10.1200/JCO.2012.47.7521
12. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA (2010) Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70:6171–6180. doi:10.1158/0008-5472.CAN-10-0153
13. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70:3526–3536. doi:10.1158/0008-5472.CAN-09-3278
14. Ozao-Choy J, Ma G, Kao J et al (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69:2514–2522. doi:10.1158/0008-5472.CAN-08-4709
15. Farsaci B, Higgins JP, Hodge JW (2012) Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 130:1948–1959. doi:10.1002/ijc.26219
16. Bose A, Lowe DB, Rao A, Storkus WJ (2012) Combined vaccine + axitinib therapy yields superior antitumor efficacy in a murine melanoma model. Melanoma Res 22:236–243. doi:10.1097/CMR.0b013e3283538293
17. Gu Y, Zhao W, Meng F, Qu B, Zhu X, Sun Y, Shu Y, Xu Q (2010) Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol 135:55–62. doi:10.1016/j.clim.2009.11.013
18. Alfaro C, Suarez N, Gonzalez A et al (2009) Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 100:1111–1119. doi:10.1038/sj.bjc.6604965
19. van Cruijsen H, van der Veldt AA, Vroling L et al (2008) Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 14:5884–5892. doi:10.1158/1078-0432.CCR-08-0656
20. Ko JS, Zea AH, Rini BI et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15:2148–2157. doi:10.1200/JCO.2012.47.7521
21. Taube JM, Anders RA, Young GD et al (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4:127ra37. doi:10.1126/scitranslmed.3003689
22. Carter L, Fouser LA, Jussif J et al (2002) PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 32:634–643
23. Najjar YG, Finke JH (2013) Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 3:49. doi:10.3389/fonc.2013.00049
24. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P (2011) MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 11:856–861. doi:10.1016/j.intimp.2011.01.030
25. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590. doi:10.1200/JCO.2008.20.1293
26. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. doi:10.1056/NEJMoa1200690
27. Panka DJ, Liu Q, Geissler AK, Mier JW (2013) Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells. Mol Cancer 12:17. doi:10.1186/1476-4598-12-17
28. Finke JH, Rini B, Ireland J et al (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 14:6674–6682. doi:10.1158/1078-0432.CCR-07-5212
29. Florcken A, Takvorian A, Van Lessen A, Singh A, Hopfenmuller W, Dorken B, Pezzutto A, Westermann J (2012) Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma. Anticancer Drugs 23:298–302. doi:10.1097/CAD.0b013e32834ee2b1
30. Bose A, Taylor JL, Alber S et al (2011) Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 129:2158–2170. doi:10.1002/ijc.25863
31. Farsaci B, Donahue RN, Coplin MA, Grenga I, Lepone LM, Molinolo AA, Hodge JW (2014) Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines. Cancer Immunol Res 2:1090–1102. doi:10.1158/2326-6066.CIR-14-0076
32. Linnemann C, Mezzadra R, Schumacher TN (2014) TCR repertoires of intratumoral T-cell subsets. Immunol Rev 257:72–82. doi:10.1111/imr.12140
33. Kvistborg P, Shu CJ, Heemskerk B et al (2012) TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 1:409–418
34. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118:3367–3377. doi:10.1172/JCI35213
35. Blank C, Kuball J, Voelkl S et al (2006) Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119:317–327. doi:10.1002/ijc.21775
36. Thompson RH, Kuntz SM, Leibovich BC et al (2006) Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66:3381–3385. doi:10.1158/0008-5472.CAN-05-4303
37. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S (2014) PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211:781–790. doi:10.1084/jem.20131916